{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:12:17Z","timestamp":1790845937265,"version":"4.1.0"},"reference-count":25,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2021,8,31]]},"DOI":"10.5582\/ddt.2021.01064","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T22:06:37Z","timestamp":1626645997000},"page":"222-224","source":"Crossref","is-referenced-by-count":17,"title":["Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021"],"prefix":"10.5582","volume":"15","author":[{"given":"Xiaoni","family":"Cui","sequence":"first","affiliation":[{"name":"Sino-Cell Biomed Co., Ltd., Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Sino-Cell Biomed Co., Ltd., Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhun","family":"Wei","sequence":"additional","affiliation":[{"name":"Institute of Innovative Drugs and Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. WHO Director-General&apos;s opening remarks at the media briefing on COVID-19 - 11 March 2020. <i>https:\/\/www.who. int\/director-general\/speeches\/detail\/who-director-general-s-opening-r<\/i><i>emarks-at-the-media-briefing-on-covid-19---11-march-2020 <\/i>(accessed March 11, 2021)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Huang Q, Yan J. SARS-CoV-2 virus: Vaccines in development. Fundam Res. 2021; 1:131-138.","DOI":"10.1016\/j.fmre.2021.01.009"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021; 21:73-82.","DOI":"10.1038\/s41577-020-00480-0"},{"key":"4","unstructured":"4. Status of COVID-19 Vaccines within WHO EUL\/PQ evaluation process. <i>WHO. https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/Status_COVID_VAX_16June2021.pdf<\/i> (accessed June 16, 2021)."},{"key":"5","unstructured":"5. mRNA vaccines to address the COVID-19 pandemic. <i>https:\/\/biontech.de\/covid-19-portal\/mrna-vaccines <\/i>(accessed June 16, 2021)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines a new era in vaccinology. Nat Rev Drug Discov. 2018; 17:261-279.","DOI":"10.1038\/nrd.2017.243"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021; 397:1819-1829.","DOI":"10.1016\/S0140-6736(21)00947-8"},{"key":"8","unstructured":"8. Thompson MG, Burgess JL, Naleway AL, <i>et al<\/i>. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - Eight U.S. locations, December 2020-March 2021. MMWR. 2021; 70:495-500."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wang Z, Muecksch F, Schaefer-Babajew D, <i>et al<\/i>. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021; 595:426-431.","DOI":"10.1038\/s41586-021-03696-9"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, Cai H, Cutler M, Cooper D, Muik A, Jansen KU, Sahin U, Xie X, Dormitzer PR, Shi PY. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021; doi: 10.1038\/s41586-021-03693-y.","DOI":"10.1038\/s41586-021-03693-y"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Aboul Fotouh K, Cui Z, Williams RO. Next-generation COVID-19 vaccines should take efficiency of distribution into consideration. AAPS PharmSciTech. 2021; 22:126.","DOI":"10.1208\/s12249-021-01974-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O&apos;Doherty M, Brown K, Cameron C, Stockton D, McMenamin J, Ramsay M. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373:n1088.","DOI":"10.1136\/bmj.n1088"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Vasileiou E, Simpson CR, Shi T, <i>et al<\/i>. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021; 397:1646-1657.","DOI":"10.1016\/S0140-6736(21)00677-2"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Pritchard E, Matthews PC, Stoesser N, <i>et al<\/i>. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. 2021; doi: 10.1038\/s41591-021-01410-w.","DOI":"10.1038\/s41591-021-01410-w"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sadoff J, Gray G, Vandebosch A, <i>et al<\/i>. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021; 384:2187-2201.","DOI":"10.1056\/NEJMoa2101544"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kifle ZD, Enyew EF, Mekuria AB. A recent achievement in the discovery and development of vaccines and therapeutic agents in the race for COVID-19 protection and treatment. J Evid Based Integr Med. 2021; 26:1-10.","DOI":"10.1177\/2515690X211003727"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mishra SK, Tripathi T. One year update on the COVID-19 pandemic: Where are we now? Acta Trop. 2021; 214:105778.","DOI":"10.1016\/j.actatropica.2020.105778"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kandeil A, Mostafa A, Hegazy RR, <i>et al<\/i>. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine: Preclinical studies. Vaccines (Basel). 2021; 9:214.","DOI":"10.3390\/vaccines9030214"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mallapaty S. WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. Nature. 2021; 594:161-162.","DOI":"10.1038\/d41586-021-01497-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Al Kaabi N, Zhang Y, Xia S, <i>et al<\/i>. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial. JAMA. 2021; 326:35-45.","DOI":"10.1001\/jama.2021.8565"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Shinde V, Bhikha S, Hoosain Z, <i>et al<\/i>. Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021; 384:1899-1909.","DOI":"10.1056\/NEJMoa2103055"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Brisse M, Vrba SM, Kirk N, Liang Y, Ly H. Emerging concepts and technologies in vaccine development. Front Immunol. 2020; 11:583077.","DOI":"10.3389\/fimmu.2020.583077"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. LiY, Tenchov R, Smoot J, Liu C, Watkins S, Zhou Q. A comprehensive review of the global efforts on COVID-19 vaccine development. ACS Cent Sci. 2021; 7:512-533.","DOI":"10.1021\/acscentsci.1c00120"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Martinez DR, Sch\u00e4fer A, Leist SR, <i>et al<\/i>. Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice. bioRxiv. 2021; doi: https:\/\/doi.org\/10.1101\/2021.03.11.434872","DOI":"10.1101\/2021.03.11.434872"},{"key":"25","unstructured":"25. COVID-19 - Landscape of novel coronavirus candidate vaccine development worldwide. <i>https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines<\/i> (accessed June22, 2021)."}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/15\/4\/15_2021.01064\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T03:55:57Z","timestamp":1632542157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/15\/4\/15_2021.01064\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2021.01064","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"article-number":"2021.01064"}}